A randomized, open-labelled, parallel, comparative study of the efficacy and tolerability of rosuvastatin in low-density lipoprotein-cholestrol reduction using different dosing regimens of 5 mg daily, 10 mg daily and 10 mg on alternate days in Hong Kong Chinese type 2 diabetic patients.

Trial Profile

A randomized, open-labelled, parallel, comparative study of the efficacy and tolerability of rosuvastatin in low-density lipoprotein-cholestrol reduction using different dosing regimens of 5 mg daily, 10 mg daily and 10 mg on alternate days in Hong Kong Chinese type 2 diabetic patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Dyslipidaemias; Lipid metabolism disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2012 Status changed from recruiting to completed as reported by ISRCTN record.
    • 31 Dec 2009 Astra Zeneca added as trial sponsor.
    • 31 Dec 2009 New source identified and integrated (Chinese Clinical Trial Register record no. ChiCTR-TRC00000677).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top